Should Pacira Pharmaceuticals Inc's (NASDAQ:PCRX) Recent Earnings Decline Worry You?

It has outperformed by 0.16% the S&P500.

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX)'s earnings per share has been growing at a 16.5 percent rate over the past 5 year when average revenue increase was noted as 77.5 percent. The institutional investor held 34,000 shares of the major chemicals company at the end of 2017Q3, valued at $2.45M, down from 42,300 at the end of the previous reported quarter. Alyeska Investment Group Lp who had been investing in Pacira Pharmaceuticals Inc for a number of months, seems to be less bullish one the $1.47B market cap company. The stock decreased 15.98% or $5.77 during the last trading session, reaching $30.33. About 1.39 million shares traded or 9.40% up from the average.

Canaccord Genuity analyst Dewey Steadman reiterated a Hold rating on Pacira Pharmaceuticals (NASDAQ: PCRX) yesterday and set a price target of $32. It has underperformed by 4.30% the S&P500. Legal General Grp Inc Inc Public Ltd stated it has 545,371 shares or 0.14% of all its holdings. Therefore 40% are positive. Weibo Corp had 23 analyst reports since August 19, 2015 according to SRatingsIntel. (NASDAQ:PCRX) on Thursday, October 26 to "Sell" rating. JP Morgan has "Overweight" rating and $140 target. Recently, analysts have updated the overall rating to 2.42. The firm earned "Hold" rating on Thursday, August 27 by Summit Research. Jefferies maintained the stock with "Buy" rating in Friday, July 14 report. The rating was maintained by Jefferies on Tuesday, October 3 with "Buy". The firm earned "Buy" rating on Monday, November 20 by Wedbush.

Investors sentiment decreased to 1.4 in 2017 Q3. Its down 1.07, from 2.62 in 2017Q2. It improved, as 93 investors sold TSLA shares while 134 reduced holdings. 40 funds opened positions while 125 raised stakes. 125.34 million shares or 324.34% more from 29.54 million shares in 2017Q2 were reported. Relative Volume (or RVOL) is a volume indicator, meaning it helps measure investor interest in a stock. (NYSE:HI). Vanguard reported 5.55M shares stake. 4,526 are owned by Mirae Asset Investments Communication Limited. Brookfield Asset Management has 0% invested in Bunge Limited (NYSE:BG) for 5,500 shares. (NYSE:PFE). The Iowa-based Btc Mgmt Inc has invested 0.76% in Pfizer Inc. First Manhattan has invested 0% of its portfolio in Weibo Corporation (NASDAQ:WB). Janney Montgomery Scott Lc holds 0.07% or 47,716 shares. Pinebridge Invs Ltd Partnership invested 0.27% in Pfizer Inc. Moreover, Manufacturers Life Ins The has 0% invested in W. R. Grace & Co. M&T Bancshares holds 0% in W. R. Grace & Co. Ameritas Investment Partners Inc. now owns 3,449 shares of the company's stock worth $165,000 after buying an additional 302 shares during the last quarter. Parametric Portfolio Associates LLC now owns 111,193 shares of the company's stock valued at $5,304,000 after buying an additional 22,949 shares during the period. Caisse De Depot Et Placement Du Quebec accumulated 67,214 shares. Alexandria Capital, Virginia-based fund reported 122 shares.

Investors sentiment increased to 1.06 in 2017 Q3. Its up 0.03, from 1.27 in 2017Q2. HASTINGS PAUL J had sold 1,044 shares worth $37,741. 73 funds opened positions while 223 raised stakes. Sei holds 522,579 shares. Mutual Of America Cap Mgmt holds 0.09% or 151,078 shares. The Pennsylvania-based Nationwide Fund Advsr has invested 0.01% in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) or 3,461 shares. (NASDAQ:PCRX). Spectrum Mngmt Group Incorporated has 4,418 shares for 0.05% of their portfolio. 25,000 are owned by Opus Point Prtnrs Limited Liability. (NASDAQ:REIT). Wespac Limited Co invested in 7,347 shares. Voya Limited Liability Com reported 590,995 shares. Moreover, Westfield Management LP has 0.37% invested in Pacira Pharmaceuticals, Inc. New York REIT, Inc. (NASDAQ:PCRX). Jacobs Levy Equity Management owns 0.01% invested in Pacira Pharmaceuticals, Inc. (NASDAQ:TSLA) or 750 shares.

EPS growth estimate for this year is set at -114.50%.The earnings per share (EPS) formula is stated as earnings available to common shareholders divided by number of common stock shares outstanding. Pacira Pharmaceuticals has a 52-week low of $29.81 and a 52-week high of $58.95. (NASDAQ:PCRX). Northern Trust Corp, Illinois-based fund reported 498,638 shares. The consensus mean EPS for the current quarter is at $0.1 derived from a total of 18 estimates from the analysts who have weighed in on projected earnings. On Tuesday, August 15 STACK DAVID M sold $1.05M worth of Pacira Pharmaceuticals, Inc. 1 is equivalent to a buy rating, 3 a hold rating, and 5 a sell rating. Therefore 80% are positive.

In response, four brokerages chimed in with price-target cuts for PCRX stock, including to $32 from $41 at BMO Capital. (NASDAQ:PCRX) has "Neutral" rating given on Thursday, December 1 by Goldman Sachs. Wedbush maintained the stock with "Buy" rating in Wednesday, July 19 report. The rating was maintained by BMO Capital Markets on Wednesday, November 8 with "Hold". Oppenheimer maintained Ecolab Inc. On Friday, July 1 the stock rating was downgraded by Brean Capital to "Hold". Wedbush maintained the shares of PCRX in report on Thursday, January 4 with "Buy" rating. (NYSE:PFE) on Wednesday, November 25 to "Neutral" rating. Piper Jaffray maintained the stock with "Buy" rating in Friday, October 6 report. The firm has "Underperform" rating by Wolfe Research given on Wednesday, March 1.

Latest News